Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CDA | P32320 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine SCHEMBL788633 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL12398456 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14126216 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL12371275 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL10813322 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL13714005 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL320217 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL16284117 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119818525-A | Cytarabine amino acid ester composition and application thereof | 沈阳信达泰康医药科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12551497-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545914-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028631-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| CN-1889970-A | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | INTERMUNE INC (US) | 2007-01-03 | — | — | CN | disclosed |
| US-20060269517-A1 | Use of alpha-glucosidase inhibitors to treat alphavirus infections | INTERMUNE, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0788506-A2 | L-RIBOFURANOSYL NUCLEOSIDES | GENENCOR INTERNATIONAL, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5559101-A | ANTITUMOR, ANTICARCINOGENIC, HIV | GENENCOR INTERNATIONAL, INC. (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | LMNA 528/4885MTOR 4719/4885THRB 1267/4885 |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFH, SSB, RNASEH1 | LMNA 103/4885MTOR 4451/4885THRB 3720/4885 |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | TMPRSS2, TMPRSS11D, TMPRSS4 | LMNA 303/4885MTOR 3137/4885THRB 2124/4885 |
| US-20260028631-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | KHK, HK2, HK1 | LMNA 426/4885MTOR 2988/4885THRB 1008/4885 |
| US-12545914-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | IGF2BP2, TEK, IGF2BP3 | LMNA 531/4885MTOR 3596/4885THRB 552/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | LMNA 3227/4885MTOR 4649/4885THRB 2032/4885 |
| US-20060269517-A1 | Use of alpha-glucosidase inhibitors to treat alphavirus infections | GBA3, GAA, GANAB | LMNA 2150/4885MTOR 2590/4885THRB 4133/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | LMNA 443/4885MTOR 4845/4885THRB 181/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | LMNA 20/4885MTOR 4722/4885THRB 2078/4885 |
| US-12551497-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | NSUN2, MTAP, NSUN3 | LMNA 1458/4885MTOR 3434/4885THRB 3295/4885 |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | LMNA 4303/4885MTOR 1759/4885THRB 3314/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | LMNA 625/4885MTOR 523/4885THRB 4797/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | LMNA 2597/4885MTOR 4616/4885THRB 1508/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | LMNA 1116/4885MTOR 3299/4885THRB 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.